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Abstract Gouty arthritis is an inflammatory condition
associated with debilitating clinical symptoms, functional
impairments, and a substantial impact on quality of life.
This condition is initially triggered by the deposition of
monosodium urate crystals into the joint space. This causes
an inflammatory cascade resulting in the secretion of
several proinflammatory cytokines and neutrophil recruit-
ment into the joint. While generally effective, currently
available agents are associated with a number of adverse
events and contraindications that complicate their use.
Based on our increased understanding of the inflammatory
pathogenesis of gouty arthritis, several new agents are
under development that may provide increased efficacy and
reduced toxicity.
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Introduction
There are an estimated 5–6 million individuals in the USA
with gout [1, 2]. This condition is encountered more
commonly in men than women, although among women
the prevalence increases after menopause [3]. Prevalence
also increases dramatically with age, with almost 12% of
males aged 70–79 years affected compared with <3% in
men younger than 50 years (Fig. 1)[ 1, 2]. Given its
demographics among the aging population, patients with
gout frequently present with multiple comorbidities: up
to 58% of patients with gout have comorbid hyperten-
sion, 45% have a comorbid lipid disorder, 33% have
both hypertension and a lipid disorder, and 20% have
comorbid diabetes mellitus [4]. Gout therefore represents
a condition of the aging population where effective
management can be frequently complicated by substantial
comorbidities.
Urate levels in the body are balanced through diet,
biosynthesis, and excretion, with overproduction or
insufficient renal clearance leading to chronic hyperuri-
cemia [5]. The pronounced increases in the plasma
concentration of urate that occur during chronic hyper-
uricemia can lead to supersaturation, and at concen-
trations >6.8 mg/dL, precipitation of monosodium urate
(MSU) crystals can occur [6]. Acute gouty arthritis
develops when MSU crystal deposits around a joint are
released into the joint space causing inflammation. Until
recently, the molecular components of this inflammation
were poorly understood. For example, not all individuals
with elevated levels of uric acid develop gouty arthritis,
there being other factors that potentially facilitate the
process. However, recent research has revealed that
interleukin (IL)-1β represents a key inflammatory medi-
ator in this pathway, and, as such, a viable therapeutic
target. The aim of this review is to summarize the current
understanding of the role of IL-1β in the inflammation
seen in patients with gouty arthritis and to provide an
overview of current treatment options with a focus on
recent additions to the therapeutic management of this
painful condition.
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Gouty arthritis is caused by the inflammatory reaction that
arises in response to the deposition of MSU crystals into the
joints of patients with hyperuricemia. This MSU-induced
inflammation is driven by components of the innate
immune system which normally provide the initial nonspe-
cific immune response to invading pathogens. Research has
shown that injured and dying mammalian cells release uric
acid, which forms MSU crystals that activate innate
immunity in a manner similar to that caused by microbial
infection [7]. The initial process of the gouty arthritis
inflammatory response occurs when macrophages that are
present within the joint space phagocytose MSU crystals
(Fig. 2). This internalization of MSU crystals then triggers
the formation of a protein scaffold known as an inflamma-
some within the cytosol of the macrophage. The inflamma-
some is a high-molecular weight protein complex that
provides a platform for the enzymatic processing of inactive
pro-IL-1β into biologically active IL-1β, which is then
secreted from the cell [8]. Interestingly, MSU crystals alone
may not be sufficient to trigger the activation/release of IL-
1β from macrophages, instead requiring co-stimulation
with free fatty acids or lipopolysaccharide to release IL-
1β [9]. Given that the consumption of alcohol or a large
meal can lead to increases in free fatty acid concentrations,
it stands to reason that the involvement of free fatty acids in
triggering release of IL-1β may be an important factor in
the development of gouty arthritis flares [9].
IL-1β is the pivotal inflammatory mediator that regulates
cell proliferation, differentiation, and apoptosis in gouty
arthritis (Fig. 2)[ 10]. This proinflammatory cytokine can
induce the expression of a wide range of inflammatory
mediators that are directly responsible for neutrophil influx
to the synovium, a hallmark of gouty arthritis [10].
Activation of the IL-1 receptor on endothelial cells by IL-
1β has been shown to be a fundamentally critical step in
the development of MSU-induced inflammation using
genetic knockout rodent models. IL-1 receptor activation
facilitates the transcription of proinflammatory cytokines
and chemokines that drive subsequent inflammatory pro-
cesses [8, 11]. Furthermore, neutrophil influx results in
further phagocytosis of MSU crystals and the perpetuation
of both IL-1β release and its associated inflammatory
processes. Strategies that reduce circulating IL-1β, includ-
ing antibodies to IL-1β and murine IL-1 trap, have been
shown to greatly reduce MSU-induced peritonitis in mice
[11].
Over time, the acute inflammation accompanying repeated
flares of gouty arthritis can culminate in pathologic joint
damage. Prolonged accumulation of MSU crystals gives rise
to tophi which consist of MSU crystals in a matrix of lipids,
protein, and mucopolysaccharides [12]. Enzymes, such as
matrix metalloproteinases, and bone-resorptive osteoclasts
are produced locally within these tophi, resulting in
progressive bone erosion [12]. In addition, the elevated
levels of proinflammatory cytokines that arise during flares
of gouty arthritis may also contribute to bone damage. IL-1
is a key molecule in the process of bone and cartilage
damage and plays a critical role in osteoclast formation [13].
Management of gouty arthritis
Treatment of gouty arthritis has three phases: control of the
acute attack/flare, control of hyperuricemia, and then
prophylaxis.
Acute attack
During the acute attack, nonsteroidal anti-inflammatory
drugs (NSAIDs) and colchicine are considered as first-line
treatment for relief of acute pain associated with flares of
gouty arthritis (Table 1)[ 14]. Among the NSAIDs,
indomethacin and naproxen have labeled approval for use
in acute gouty arthritis while ibuprofen and celecoxib are
not approved. Given the potential for gastrointestinal
ulceration and bleeding, as well as the exacerbation of
common comorbidities in this patient population (e.g., renal
dysfunction, hypertension), it is the opinion of this author
that the use of nonselective NSAIDs in patients over the
age of 65 years be avoided, particularly in the presence of
significant underlying renal dysfunction and in elderly
patients with a previous history of gastrointestinal ulcera-
tion and bleeding.
Colchicine is an established treatment for acute gouty
arthritis but only recently has received approval from the
US Food and Drug Administration for use in this indication
(Colcrys
TM (colchicine, USP) tablets for oral use; Mutual
Fig. 1 Prevalence of gout in the USA according to age [1, 2]
14 Clin Rheumatol (2012) 31:13–21Pharmaceutical Company, Inc., Corona, CA). This approval
was based on the results of the placebo-controlled Acute
Gout Flare Receiving Colchicine Evaluation study, which
demonstrated that colchicine, at low (1.8 mg) or high
(4.8 mg) doses, administered over 6 h was significantly
more effective than placebo at reducing pain scores.
Overall, 32.7% and 37.8% of patients receiving high-dose
and low-dose colchicine had a ≥50% reduction in pain
scores within 24 h of starting treatment, compared with
15.5% of those receiving placebo (p=0.034 and p=0.005
for comparison of high- and low-dose versus placebo,
respectively). Diarrhea was the most frequently reported
adverse event (AE) among patients receiving colchicine
(low dose, 23%; high dose, 76.9%) [15].
Systemic corticosteroids are a treatment option for
patients who have contraindications to NSAIDs and
colchicine, or who do not tolerate these first-line agents;
however, this approach is not underscored by robust clinical
trial data (Table 1)[ 14]. Intraarticular injection of a long-
acting steroid is another potential therapeutic approach that
may be effective at alleviating pain associated with an acute
monoarticular attack [14, 16].
Analysis of contraindications and prescribing practices
suggests that a large number of patients with gout have
contraindications to the currently available therapies [17].
In a retrospective database analysis of 807 patients with an
International Classification of Diseases, Ninth Revision,
Clinical modification (ICD-9-CM) code diagnosis for gout,
the prevalence of comorbidities and contraindications to
gout medications was high. In total, 89% of patients with
gout had hypertension, 63% had hyperlipidemia, 47% had
chronic kidney disease, 37% had coronary artery disease,
and 28.9% had diabetes. In addition, most patients had
multiple comorbidities with two, three, or four comorbid-
ities present in 17%, 22%, and 25% of patients, respective-
ly. The presence of these comorbidities also translated into
high rates of contraindications to gout therapy. More than
90% of patients had ≥1 contraindication to NSAID use,
95% had ≥1 contraindication to glucocorticoid use, and at
least 50% had at least one contraindication to colchicine
use. In this study, each patient had a mean of 3.5
contraindications to gout drugs [17].
This ineligibility for current treatment that exists among
a large number of patients with gout has resulted in the
Fig. 2 IL-1β signaling leads to
recruitment of neutrophils and
amplification of an acute in-
flammatory cascade. IL inter-
leukin, MSU monosodium urate,
TNF-α tumor necrosis factor
alpha
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16 Clin Rheumatol (2012) 31:13–21need for alternative treatment options. One such therapeutic
alternative has arisen from the increasing understanding of
the role of IL-1β in the underlying inflammatory response
seen in gouty arthritis. Treatment strategies that aim to
interrupt the IL-1β molecular pathway will theoretically
reduce the inflammation and pain experienced by patients
during flares of gouty arthritis, and clinically, this treatment
approach has shown considerable early promise.
New therapeutic agents studied for acute management:
IL-1β signaling blockade
Anakinra is a recombinant, nonglycosylated form of the
human IL-1 receptor antagonist approved for use in patients
with moderate to severely active rheumatoid arthritis who
have failed first-line therapies. Studies in patients with gout
are restricted to small case series in ten or fewer patients
[18, 19]. In one case series, patients with a history of
recurrent gouty arthritis or tophaceous gout received open-
label anakinra at a dose of 100 mg/day administered as a
subcutaneous injection for 3 days [19]. All patients
responded rapidly to treatment, with a mean decrease in
pain rating of 79% by day 3 after the initial injection.
Another case series of ten patients also reported favorable
short-term responses to anakinra; however, recurrent flares
after discontinuation of treatment were common, occurring
in nine of ten treated patients [18].
A small proof-of-concept study has investigated the
efficacy and safety of rilonacept, a soluble receptor–Fc
fusion protein trap for and inhibitor of IL-1α and IL-1β,i n
the treatment of chronic gouty arthritis [20]. In this 14-week
study, ten patients with chronic active gouty arthritis
underwent a 2-week lead-in period (during which patients
received single-blind placebo) and then received rilonacept
for 6 weeks followed by a 6-week follow-up period.
Rilonacept was administered as a single loading dose of
320 mg during week 2 followed by 160 mg once weekly
during weeks 3–7. Compared with the placebo run-in
phase, treatment with rilonacept was associated with a
significant improvement in patient pain scores, global
assessment of “feeling well” and symptom/severity adjust-
ed scores. There was also a significant reduction in levels of
high-sensitivity C-reactive protein (CRP) compared with
the lead-in phase. One patient discontinued during the
second week of active treatment because of severe injection
site erythema and induration related to study medication,
and three patients developed anti-rilonacept antibodies [20].
Canakinumab (ACZ885) is a fully human monoclonal
antibody that neutralizes the activity of human IL-1β,l e a d i n g
to inhibition of IL-1β signaling and suppression of inflam-
mation [21]. It has shown activity in small studies of patients
with rheumatoid arthritis and cryopyrin-associated periodic
syndrome and is approved in the USA and Switzerland for
treatment of Muckle–Wells syndrome and familial cold auto-
inflammatory syndrome [21]. In a phase 2 dose-ranging
study in patients with difficult-to-treat gouty arthritis,
canakinumab (10, 25, 50, 90, and 150 mg as single
intramuscular doses) was associated with a dose-related
decline in pain rating at 72 h after administration [22]. At the
highest dose, canakinumab resulted in a significantly greater
mean reduction in pain compared with intramuscular
injection of triamcinolone acetonide (40 mg) at 24 h, 48 h,
72 h, 4, 5, and 7 days after dosing. All doses evaluated
resulted in a numerically greater reduction in pain at 72 h (as
assessed using a visual analog scale) compared with
triamcinolone acetonide; however, evaluation of pain levels
at 48 h postinjection indicates that a canakinumab dose of
23 mg (95% confidence interval [CI], 3–96 mg) has
equivalent efficacy to triamcinolone acetonide (40 mg).
Furthermore, the incidence of flare at 8 weeks posttreatment
was 3.7% in patients receiving canakinumab (150 mg) and
45% in those who received triamcinolone acetonide. Cana-
kinumab treatment (at doses 20–150 mg) was also associated
with normalization of CRP and serum amyloid A protein
(SAA) levels by day 7 after treatment; however, these
inflammatory markers were largely unaffected by triamcin-
olone acetonide. There were four serious AEs in patients
receiving canakinumab (appendicitis, n=2; bronchitis, n=1;
and carotid artery stenosis, n=1), all considered to be
unrelated to study medication. The tolerability profile was
otherwise similar in patients receiving canakinumab and
triamcinolone acetonide [22]. Subsequent analyses of the
data from this study have reported that at a dose of 150 mg,
canakinumab shows superiority over triamcinolone acetonide
(40 mg) in terms of pain relief, reduction in signs of
inflammation (as assessed using a Likert scale and also
through inflammatory markers), and health-related quality of
life measures [23]. Additional phase 3 studies of canakinu-
mab in patients with gouty arthritis are ongoing [21].
Agents that interfere with IL-1β signaling therefore appear
to represent an important therapeutic class in the future
treatment of gouty arthritis; however, clinical experience with
these agents in patients with rheumatoid arthritis suggests that
their use may be associated with an increased risk of infection
[24]. At this time, the extent to which this association is
related to comorbidities that are unique to patients with
rheumatoid arthritis is unknown. Data from additional
randomized controlled trials in patients with gouty arthritis
will help provide a better understanding regarding the
benefit-risk profile of these agents.
Chronic management
In patients who experience recurring flares of gouty
arthritis, long-term chronic management strategies should
be implemented to mitigate the incidence of acute attacks.
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Weight reduction is recommended for overweight or obese
patients [16], supplemented by an increased intake of
selected food types. Patients should be encouraged to
include skimmed milk, low-fat yogurt, soy beans, vegetable
protein sources, and cherries in their diets, and high-purine
foods such as liver, kidney, shellfish, and red meat should
be discouraged [16, 25, 26]. Alcohol consumption
<21 units/week for men and <14 units per week for women
is also strongly advised—beer, stout, and port should be
avoided, and patients should be encouraged to maintain
3 days each week in which alcohol is completely avoided
[16]. Finally, management strategies should also take into
account concomitant medications that could increase serum
uric acid levels. Thiazide or loop diuretics, low-dose
aspirin, cyclosporine, niacin, pyrazinamide, and ethambutol
may each cause increased serum uric acid levels [6].
Pharmacologic management
Patients who experience recurrent acute attacks, arthropa-
thy, tophi, or radiographic changes are candidates for urate-
lowering therapy (Table 2)[ 14]. The therapeutic goal is to
promote crystal dissolution and prevent crystal formation
by maintaining serum urate concentrations below the
saturation point for MSU [14, 16].
Allopurinol and probenecid have for many years
represented the cornerstone of treatment for chronic gouty
arthritis. Allopurinol, a xanthine oxidase inhibitor that acts
by blocking the production of uric acid through a reduction
in purine catabolism, is considered to be an appropriate
long-term urate-lowering therapy (Table 2)[ 14]. Typical
AEs associated with allopurinol include diarrhea, nausea,
and increases in alkaline phosphatase, ALT, and AST levels
(Allopurinol (tablet); Watson Laboratories, Inc., Corona,
CA). Probenecid is a uricosuric agent that increases
excretion of uric acid by blocking tubular reabsorption
(Table 2) (Probenecid; Watson Pharmaceuticals Inc., Coro-
na, CA). It is used largely as an alternative to allopurinol,
although it is considered less efficacious [14].
Febuxostat is a more recent addition to treatment options
for chronic gouty arthritis. It is a nonpurine, xanthine
oxidase inhibitor approved for the chronic management of
hyperuricemia in patients with gouty arthritis (Table 2)
(Uloric® (Febuxostat) tablet for oral use; Takeda Pharma-
ceuticals America, Inc., Deerfield, IL). Like allopurinol,
febuxostat inhibits the synthesis of uric acid by xanthine
oxidase. However, animal studies have suggested it
provides a more potent and longer-lasting hypouricemic
effect compared with allopurinol, an effect attributed to its
potent inhibition of both oxidized and reduced forms of
xanthine oxidase [27]. The approval of febuxostat was
based on the data from three phase 3 clinical trials,
Allopurinol- and Placebo-controlled Efficacy study of
febuxostat (APEX) [28], Febuxostat versus Allopurinol
Controlled Trial (FACT) [29], and CONFIRMS [30].
The phase 3 clinical studies showed febuxostat (80–
240 mg/day) to be significantly more effective than
allopurinol (200–300 mg/day). In all studies, the propor-
tion of patients with a urate concentration <6 mg/dL at
the end of treatment (the primary end point) was
significantly higher among patients receiving febuxostat
compared with allopurinol [28–30]. However, it is also
noteworthy that these studies did not allow for allopuri-
nol to be dose titrated above 300 mg/day, despite higher
doses being recommended for patients with moderately
severe tophaceous gout (Allopurinol (tablet); Watson
Laboratories, Inc., Corona, CA). In APEX and FACT,
prophylaxis against gout flares with naproxen (250 mg
twice daily) or colchicine (0.6 mg/day) was administered
for the first 8 weeks of treatment, and in both studies the
incidence of gout flares was highest during the 4 weeks
immediately following withdrawal of prophylaxis [31].
However, in CONFIRMS, prophylaxis for gout flares was
administered for the full 6-month treatment period, and
unlike the previous two studies, there was no peak in the
incidence of flares at weeks 9–12, but instead a steady
decline in the incidence of flares throughout the 6-month
treatment period [32].
Overall, AEs were similar across all treatment groups in
these studies [28–30]. In APEX, febuxostat at 240 mg/day
was associated with high levels of diarrhea and dizziness,
and the incidence of hypertension was also higher in the
febuxostat 80-mg/day arm [28]. Abnormal findings on liver
function tests and rash-related AEs were generally similar
across treatment arms, and AEs leading to treatment
withdrawal were similar in patients receiving febuxostat
and allopurinol [28]. In FACT, the incidence of treatment-
related AEs was also similar between treatment arms, with
liver function abnormalities, diarrhea, and headache occur-
ring at a similar incidence in each treatment arm. Abnormal
liver function tests and rash were the most frequent AEs
leading to treatment discontinuation in patients receiving
febuxostat [29]. In CONFIRMS, rash, liver function
abnormalities, and diarrhea occurred at broadly similar
rates in patients receiving febuxostat or allopurinol [30].
Premature treatment withdrawal because of an AE was also
similar across treatment arms (6.5–8.5%) [30]. Overall,
pooled study data of the most frequently reported AEs for
febuxostat and allopurinol showed similar rates of liver
function abnormalities (4.6–6.6% vs 4.2%, respectively),
nausea (1.1–1.3% vs 0.8%, respectively), arthralgia (0.7–
1.1% vs 0.7%, respectively), and rash (0.5–1.6% vs 1.6%,
respectively) (Allopurinol (tablet); Watson Laboratories,
Inc., Corona, CA).
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Approved
indication
Mechanism
of action
Dosing regimen Other
recommendations
Safety
Chronic
hyperuricemia
Allopurinol
a Management of
patients with
signs and
symptoms of
primary or
secondary gout
b
Xanthine
oxidase
inhibitor
Starting dose of 100 mg/day
increasing at 100-mg/day
increments each week until
sUA≤6 mg/dL
Prophylaxis with
colchicine or NSAID
to suppress gouty
attacks as needed
Contraindicated in patients
with history of severe
reaction to allopurinol
Maximum recommended
dose=800 mg/day
Maintain fluid intake to
yield daily urine output
of ≥2L
Skin rash can be severe and
sometimes fatal
Discontinue at the first
sign of rash
Other AEs include diarrhea,
nausea, and alkaline
phosphatase increase
Febuxostat
c Chronic
management of
hyperuricemia
in patients with
gout
Xanthine
oxidase
inhibitor
40 mg OD, increasing to 80 mg
OD after 1 week in patients
with sUA≥6 mg/dL
Prophylaxis with
NSAID or colchicine
for up to 6 months
recommended to
minimize gout flares
Contraindicated in patients
receiving azathioprine or
mercaptopurine
Cardiovascular
thromboembolic events and
liver enzyme elevations may
be more common
Other AEs include nausea,
arthralgia, and rash
Probenecid
d Treatment of
hyperuricemia
associated with
gout and gouty
arthritis
Uricosuric
agent which
blocks
tubular
reabsorption
of uric acid
250 mg BID for 1 week, then
500 mg BID thereafter
e
Alkalization of the urine
with sodium
bicarbonate (3–7.5 g/
day) or potassium
citrate (7.5 g/day)
recommended
Contraindicated in patients with
hypersensitivity to
probenecid, children aged
<2 years, and is not
recommended in patients with
known blood dyscrasias or
uric acid kidney stones
Colchicine or alternative
symptomatic therapy
advised for patients
with exacerbation of
gout following therapy
Treatment
refractory
disease
Pegloticase
f Treatment of
chronic gout in
adult patients
refractory to
conventional
therapy
Pegylated
uricase
enzyme
8 mg as an intravenous infusion
every 2 weeks premedicated
with antihistamines and
corticosteroids; optimal
treatment duration not
established
Prophylaxis with
NSAID or colchicine
recommended to
minimize gout flares
Black box warning for
anaphylaxis and infusion
related reactions
Discontinue therapy in
patients with uric acid
levels >6 mg/dL
g
Contraindicated in patients
with glucose-6-phosphate
dehydrogenase deficiency
BID twice daily, OD once daily, sUA serum uric acid
aAllopurinol (tablet) (2006) Watson Laboratories, Inc., Corona, CA
bAcute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy
cUloric® (Febuxostat) tablet for oral use (2009) Takeda Pharmaceuticals America, Inc., Deerfield, IL
dProbenecid (2011) Watson Pharmaceuticals Inc., Corona, CA
eDaily dose can be increased up to a maximum of 2,000 mg/day in patients with uncontrolled hyperuricemia or with renal impairment
fKRYSTEXXA™ (pegloticase) injection, for intravenous infusion (2010) Savient Pharmaceuticals, Inc., East Brunswick, NJ
gRisk of anaphylaxis and infusion reactions is higher among patients who have lost therapeutic response
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Most mammals possess the enzyme urate oxidase that
catalyzes the conversion of uric acid to 5-hydroxy isourate
and hydrogen peroxide, ultimately leading to the formation
of allantoin, which is a more soluble and easily excreted
purine metabolite [33, 34]. However, as a result of
mutations to the urate oxidase gene during evolution, this
pathway for urate elimination is not functional in humans.
Pegloticase is a genetically engineered pegylated mamma-
lian urate oxidase enzyme indicated for the treatment of
chronic gout in adult patients refractory to conventional
therapy, such as those who have failed to achieve normal
serum urate levels or whose symptoms are inadequately
controlled with xanthine oxidase inhibitors at the maximum
tolerated dose (Table 2) (KRYSTEXXA™ (pegloticase)
injection, for intravenous infusion; Savient Pharmaceuti-
cals, Inc., East Brunswick, NJ).
In a randomized phase 2 study of 41 patients with gouty
arthritis who had been unsuccessfully treated with, or had
contraindication to, urate-lowering therapy, pegloticase at
doses of 4 or 8 mg every 2 weeks, or 8 or 12 mg every
4 weeks, was associated with a rapid decrease in plasma urate
levelsto≤6mg /d L[34] .T h i sd e c r e a s ew a ss e e nw i t h i n6ho f
commencing treatment, and was sustained for the 10-week
treatment period in all dose groups, except the 4-mg-every-2-
weeks group. Two patients experienced rapid regression of
tophi within 12 weeks of starting treatment [35]. The most
commonly reported AEs were nephrolithiasis (15%) and
arthralgia (12%), followed by anemia, dyspnea, headache,
muscle spasms, nausea, and pyrexia, each reported in 10% of
patients. Overall, 76% of patients showed anti-pegloticase
immunoreactivity during the study, which was associated
with a shortened pegloticase half-life and an increase in urate
area under the curve. Among patients who were antibody
negative, treatment response was 100% [34].
Subsequent phase 3 studies have also confirmed the
urate-lowering ability of pegloticase in patients with
severe gouty arthritis who are refractory or intolerant to
allopurinol and with serum urate ≥8m g / d L[ 36]. In two
24-week, randomized, double-blind, placebo-controlled
studies, the proportion of patients with plasma urate levels
<6 mg/dL for ≥80% of the time during months 3 and 6
(corresponding to the 4-week periods immediately follow-
ing week 9 and week 21 infusions) was significantly
higher in patients receiving pegloticase (8 mg biweekly or
every 4 weeks) compared with those receiving placebo
(42% and 35% vs 0%, p<0.001 for both comparisons).
Complete response in one or more tophi (defined as 100%
reduction in tophus area) was seen in 40% of patients
receiving biweekly pegloticase, 21% of those receiving
monthly pegloticase, and 7% of those receiving placebo
(biweekly vs placebo, p=0.002; monthly vs placebo p=
0.2). Pegloticase antibodies were present in 134 of 150
treated patients and were significantly associated with an
impaired response to therapy and a higher risk of infusion-
related reactions. Gout flares (despite prophylaxis with
colchicine or NSAIDs throughout the study) and infusion-
related reactions (despite pretreatment with fexofenadine,
acetaminophen, and hydrocortisone) were the most fre-
quently reported AEs [36].
Summary
Gouty arthritis is the most common type of inflammatory
arthritis in males over the age of 40 years. Unfortunately, it is
also one of the most misunderstood diseases. Oversaturation
of serum urate and formation of MSU crystals activates the
inflammasome, resulting in the maturation of IL-1β,a
proinflammatory cytokine. This begins a cascade of events
that culminates in neutrophil influx into the synovium and the
highly inflammatory nature of acute gouty arthritis. Manage-
ment of this condition requires treatment of the acute attack,
addressing the underlying metabolic abnormality of the
hyperuricemia, and providing prophylaxis to the patient to
prevent recurrence until normouricemia is achieved. Unfortu-
nately, a large proportion of especially elderly patients are
either unresponsive to or intolerant of the use of currently
available medications such as xanthine oxidase inhibitors and
NSAIDs because of the presence of significant comorbidities
such as renal failure, cardiovascular disease, or being at risk
for gastrointestinal bleeding. In these patients, the advent of
IL-1blockaderepresentsa promisingnew treatment modality.
Results from the completed phase 3 studies of these agents,
once available, will help us to better understand their benefit-
risk ratio.
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